The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.
Nadia MarascioCarmen De CaroAngela QuirinoMazzitelli MariaEmilio RussoCarlo TortiGiovanni MateraPublished in: Journal of clinical medicine (2022)
Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut-liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut-liver axis.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- sars cov
- microbial community
- public health
- healthcare
- end stage renal disease
- newly diagnosed
- ejection fraction
- coronavirus disease
- mental health
- stem cells
- gene expression
- oxidative stress
- hiv infected
- patient reported outcomes
- genome wide
- quality improvement
- wastewater treatment
- bone marrow
- copy number
- antiretroviral therapy
- drug induced
- health insurance
- replacement therapy
- health information
- hiv infected patients
- affordable care act